Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at ...

Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...

Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...

Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare ...

Learn More » Importantly, the Nasdaq has officially entered market correction territory, meaning it has fallen at least 10% ...

On an intraday basis between Feb. 18 and March 4, the innovation-driven Nasdaq Composite lost close to 11% of its value. Uncertainty tied to President Donald Trump's tariffs is the primarily ...

The ageless Dow Jones Industrial Average, benchmark S&P 500, and growth-dominated Nasdaq Composite (NASDAQINDEX: ^IXIC) have all soared to numerous record-closing highs. But following this monster ...

Bell Works, the setting of the hit serial for Apple TV+, is now a tourist attraction, drawing fans to the architectural wonder. Decades before “Severance,” Lumon’s fictional headquarters had ...

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s share price was down 6.4% during mid-day trading on Monday after Piper Sandler lowered their price target on the stock from $53.00 to $ ...